Relief Therapeutics

Name

Relief Therapeutics

Legal name

Relief Therapeutics Holding SA

Website

https://relieftherapeutics.com

Company type

Public

Founded year

2013

Operating status

Acquired

Headcount range

51–100 employees

Short description

Relief Therapeutics was a Swiss clinical-stage biopharmaceutical company. Following its December 2025 merger with NeuroX Group, the combined entity operates as MindMaze Therapeutics, integrating digital neurotherapeutics platforms with pharmaceutical pipelines for stroke, Parkinson's, PKU, and rare lung diseases.

Ownership category

akta.pro rank

Product category

Digital Neurotherapeutics

NAICS

Offices of Physical, Occupational and Speech Therapists, and Audiologists (621340), Home Health Care Services (62161), Other Computer Related Services (541519), Offices of Physical, Occupational and Speech Therapists, and Audiologists (62134)

SIC

Services-Misc Health & Allied Services, Nec (8090), Services-Health Services (8000), Services-Home Health Care Services (8082), Services-Prepackaged Software (7372)

akta.pro primary industry

Digital Rehabilitation & Physical Therapy Therapeutics (HLACANAJ)

akta.pro secondary industries

Behavioral Health & Neurocognitive Therapeutics (Digital) (HLACANAI), Neurology & CNS Specialty Pharmaceuticals (HLAIACAC), Medication Adherence, Digital Therapeutics & Remote Coaching (condition-specific programs) (HLALAFAF), Chronic Disease Management Pathways (e.g., diabetes, CHF, COPD) (HLACAGAG)

Keywords

• Digital neurotherapeutics
• Neurorehabilitation platform
• Motion analytics
• Rare disease therapeutics
• Behavioral biotechnology

Headquarters

HQ city

Lausanne

HQ country

Switzerland

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Software

Cost components

Technology or R&D, Operations, Personnel, Marketing or Sales

Revenue model

1. Digital Neurotherapeutics: Revenue generated from commercially available precision neurotherapeutic solutions deployed in clinical settings, including MindMotion GO, MindPod, and other digital therapy products. The company generates revenue from therapy delivery and related services.
2. Pharmaceutical Products: Revenue from pharmaceutical pipeline including RLF-OD032 (sapropterin dihydrochloride for phenylketonuria) and aviptadil for rare lung diseases. Products were in various stages from development to commercial.
3. Home-Based Therapy: Revenue from CMS Category III reimbursed home-based AI-driven neurorehabilitation services, representing a reimbursable clinical service pathway.

Pricing tiers

Go-to-market motion1 record

Distribution channels4 records

Marketing channels3 records

Core offering

Relief Therapeutics develops and commercializes precision neurotherapeutic solutions combining behavioral therapy, proprietary software, smart peripheral devices, and AI-driven data analytics for patients with neurological conditions including stroke, Parkinson's disease, Alzheimer's, and traumatic brain injury. The product portfolio spans the MindMaze Platform ecosystem (MindPod, MindMotion GO, Izar, Physilog, ToapRun, Companion) deployed in hospitals and home settings, complemented by a pharmaceutical pipeline addressing rare diseases such as RLF-OD032 for phenylketonuria and aviptadil for rare lung diseases.

Product overview

Relief Therapeutics, now operating as MindMaze Therapeutics following its December 2025 merger with NeuroX Group, offers a platform-plus-modules architecture combining precision digital neurotherapeutics with pharmacological treatments. The MindMaze Platform serves as the core ecosystem integrating behavioral neurotherapeutics, software, devices, and data. The therapy and monitoring portfolio includes MindPod (immersive gaming-based motor and cognitive recovery), MindMotion GO (neurorehabilitation system for clinical and home settings), Izar (smart hand training peripheral), Physilog (3D motion analytics for digital biomarkers), ToapRun, and Companion. The drug development pipeline encompasses treatments for rare diseases including RLF-OD032 (phenylketonuria) and aviptadil (inhaled formulation for rare lung diseases). The combined entity holds 27+ completed clinical studies, 11 regulatory clearances, and processes over 1.2 billion data points per month.

Differentiator

Problem solved

Functional benefit

Brands

• MindPod: The immersive experience platform for brain recovery and learning with animated gaming environment designed to promote recovery of motor skill and cognitive function
• MindMotion GO
• Izar
• Physilog
• ToapRun
• Companion
• RLF-OD032

Products and services

• MindMaze Platform A treatment ecosystem redefining brain health and recovery that integrates behavioral neurotherapeutics, software, devices, and data into a unified precision neurotherapeutic platform; deployed at leading clinical centers worldwide for hospitals and neurorehabilitation facilities.
• MindPod Immersive experience platform featuring an animated gaming environment designed to promote recovery of motor skill and cognitive function with emotionally-engaging experiences; for patients with neurological conditions in clinical neurorehabilitation settings.
• MindMotion GO First-of-its-kind neurorehabilitation system providing effective behavioral neurotherapeutics in both clinical and home settings, designed to keep patients training for longer across the continuum-of-care; for hospitals, neurorehabilitation facilities, and home-based therapy.
• Izar Proprietary smart peripheral designed to improve hand motor function in patients with neurological conditions including stroke, Parkinson's, Alzheimer's, and traumatic brain injury; deployed in neurorehabilitation settings.
• Physilog Solution delivering powerful 3D motion analytics to capture, measure, and analyze a new generation of digital biomarkers for patient-centric digital motion assessments; used by clinical and research customers.
• ToapRun Therapy and monitoring device listed as part of the proprietary portfolio of solutions for precision neurotherapeutics; deployed alongside the MindMaze therapy and monitoring portfolio.
• Companion Therapy and monitoring solution included in the MindMaze portfolio of precision neurotherapeutic solutions; supports patient recovery and monitoring.
• RLF-OD032 Liquid formulation of sapropterin dihydrochloride for treating phenylketonuria (PKU), shown bioequivalent to KUVAN Powder in pivotal study with plans for new drug application submission in early 2026; U.S. and Canadian rights sold to MindMaze Therapeutics for $3 million upfront plus royalties.

Quantifiable outcome

• 60% increase in delivered therapy per day
• +2 more outcomes

Named customers1 record

Segments4 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature6 records

Partnerships

Four partnerships are on record, tiered minor, key and supporting.

• MindMaze Therapeutics (RLF-OD032 buyer)minorChannel Partner/ Reseller/ Distributor · 2 June 2026MindMaze Therapeutics is purchasing U.S. and Canadian rights to RLF-OD032 program for $3 million upfront plus royalties. The program was a legacy asset from Relief Therapeutics.
• Vibra HealthcarekeyStrategic or Co-development PartnerMulti-site real-world evidence program conducted with Vibra Healthcare demonstrating statistically significant improvements in mobility and self-care outcomes, including a 60% increase in delivered therapy per day and 77% of patients reporting improved recovery.
• SwissNeuroRehab ConsortiumkeyStrategic or Co-development PartnerCHF 11.2 million Innosuisse-backed national consortium involving Swiss university hospitals for national evidence generation program in digital neurorehabilitation.
• NICE (National Institute for Health and Care Excellence)supportingStrategic or Co-development PartnerAligning with NICE evaluation frameworks in the United Kingdom to support future reimbursement and adoption of neurotherapeutics.

Scale indicators15 records

Recent moves8 records

Expansion highlights6 records

Direct peers

• Neofect: Neofect delivers smart rehabilitation solutions including the Rapael Smart Glove and home-based therapy apps for stroke recovery. Directly comparable to Izar and MindMotion GO on home-based, gamified neurorehabilitation.
• Penumbra (REAL Immersive System): Penumbra offers the REAL Immersive System, a VR-based neurorehabilitation platform for stroke and neurological recovery. Directly comparable to MindMotion GO and MindPod as a digital neurotherapeutic for clinical and home settings.
• Bionik Laboratories: Bionik Laboratories offers robotic rehabilitation technologies for upper limb recovery following stroke and neurological injury. Directly comparable to MindMotion GO and Izar for motor skill recovery in clinical settings.
• Saebo: Saebo provides functional orthotics and rehabilitation products for stroke and neurological patients, including hand/grip devices and therapy software. Directly comparable to Izar and Companion as therapy and monitoring solutions for neurological recovery.
• Hocoma / DIH Medical: Hocoma, now part of DIH, develops robotic and sensor-based neurorehabilitation devices (Lokomat, Armeo). Directly comparable as a clinical neurorehabilitation device vendor serving hospitals and rehab centers worldwide.

Broad incumbents

• Medtronic (Neuromodulation): Medtronic operates a major neuromodulation business (deep brain stimulation for Parkinson's, spinal cord stimulation) adjacent to MindMaze's neurological disease focus. Comparable as a broad incumbent in neurology devices with overlapping therapy delivery mechanisms.
• BioMarin Pharmaceutical: BioMarin markets KUVAN (sapropterin) for phenylketonuria, the reference listed drug for Relief's RLF-OD032. Comparable as a CNS/specialty pharmaceutical incumbent in the PKU space and broader rare disease neurology.

Emerging players

• Flint Rehab: Flint Rehab develops low-cost, clinically validated neurorehabilitation devices (MusicGlove, FitMi) used in clinic and home. Comparable to MindPod and MindMotion GO as digital neurotherapeutic solutions for stroke and motor recovery.
• Constant Therapy (Linus Health): Constant Therapy, part of Linus Health, provides digital cognitive, speech, and language therapy across clinical and home settings. Comparable as a software-driven neurorehabilitation platform targeting cognitive recovery alongside motor function.

Regional players

• Elekta (Elekta ONE / Kaiku): Elekta, via its Kaiku Health subsidiary, delivers digital patient monitoring and symptom tracking for chronic conditions including oncology; comparable platform architecture for digital neuro-monitoring and patient-reported outcomes. Primary footprint is European/oncology rather than competing directly in US neurorehab.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/relief-therapeutics-holding-sa
• Xx.com/MindMazeTx
• Facebookfacebook.com/MindMazeTx

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Subsidiaries2 records

Funding overview

Funding rounds13 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A4 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Relief Therapeutics